Related references
Note: Only part of the references are listed.Small Molecule CXCR3 Antagonists
Stephen P. Andrews et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779
Belinda Nedjai et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Ligand-Biased and Probe-Dependent Modulation of Chemokine Receptor CXCR3 Signaling by Negative Allosteric Modulators
Viachaslau Bernat et al.
CHEMMEDCHEM (2015)
Chemokine receptors as therapeutic targets: Why aren't there more drugs?
Roberto Solari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
CXCR3 chemokine receptor signaling mediates itch in experimental allergic contact dermatitis
Lintao Qu et al.
PAIN (2015)
CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model
Marius Krauthausen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Boronic Acids as Probes for Investigation of Allosteric Modulation of the Chemokine Receptor CXCR3
Viachaslau Bernat et al.
ACS CHEMICAL BIOLOGY (2014)
IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: Improved PK, hERG and metabolic profiles
Anilkumar G. Nair et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor
David H. McDermott et al.
BLOOD (2014)
Spinal IFN-γ-induced protein-10 (CXCL10) mediates metastatic breast cancer-induced bone pain by activation of microglia in rat models
Huilian Bu et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Expression of CXCR3 on Specific T Cells Is Essential for Homing to the Prostate Gland in an Experimental Model of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Maria L. Breser et al.
JOURNAL OF IMMUNOLOGY (2013)
Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex
Qiuxiang Tan et al.
SCIENCE (2013)
Discovery of potent and specific CXCR3 antagonists
Xiaoqi Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection
Chung-Her Jenh et al.
BMC IMMUNOLOGY (2012)
Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3
D. J. Scholten et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3
Belinda Nedjai et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Chemical Subtleties in Small-Molecule Modulation of Peptide Receptor Function: The Case of CXCR3 Biaryl-Type Ligands
Maikel Wijtmans et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Chemokine Receptor Antagonists
James Pease et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
The blocking of CXCR3 and CCR5 suppresses the infiltration of T lymphocytes in rat renal ischemia reperfusion
Koichi Tsutahara et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation
Graeme O'Boyle et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Blocking of CCR5 and CXCR3 Suppresses the Infiltration of Macrophages in Acute Renal Allograft Rejection
Yoichi Kakuta et al.
TRANSPLANTATION (2012)
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
Dona L. Fleishaker et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Pharmacokinetics of Lisdexamfetamine Dimesylate after Targeted Gastrointestinal Release or Oral Administration in Healthy Adults
James C. Ermer et al.
DRUG METABOLISM AND DISPOSITION (2012)
CXCR3 antagonists: Quaternary ammonium salts equipped with biphenyl- and polycycloaliphatic-anchors
Maikel Wijtmans et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold
Seong Heon Kim et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists
Yuefei Shao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood
Gebhard Thoma et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model
S. Christen et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
Circulating glucose levels modulate neural control of desire for high-calorie foods in humans
Kathleen A. Page et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Effects of a calcineurin inhibitor, FK506, and a CCR5/CXCR3 antagonist, TAK-779, in a rat small intestinal transplantation model
Yuichi Takama et al.
TRANSPLANT IMMUNOLOGY (2011)
Overcoming hurdles in developing successful drugs targeting chemokine receptors
Thomas J. Schall et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Discovery of a novel series of CXCR3 antagonists
Stefano Crosignani et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Novel CXCR3 antagonists with a piperazinyl-piperidine core
Brian F. McGuinness et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Optimization of a series of quinazolinone-derived antagonists of CXCR3
Jiwen Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: Discovery, characterization and preliminary SAR of a promising lead
Gebhard Thoma et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Imidazo-pyrazine derivatives as potent CXCR3 antagonists
Xiaohui Du et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism
B. Cambien et al.
BRITISH JOURNAL OF CANCER (2009)
The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function
Jia Ni et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
CXCL10 Impairs β Cell Function and Viability in Diabetes through TLR4 Signaling
Fabienne T. Schulthess et al.
CELL METABOLISM (2009)
An Inhibitory Metabolite Leads to Dose- and Time-Dependent Pharmacokinetics of (R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in Human Subjects After Multiple Dosing
George R. Tonn et al.
DRUG METABOLISM AND DISPOSITION (2009)
Chemokine receptor antagonists: part 2
James E. Pease et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs
Emmanuelle Pradelli et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Elucidation of Binding Sites of Dual Antagonists in the Human Chemokine Receptors CCR2 and CCR5
Spencer E. Hall et al.
MOLECULAR PHARMACOLOGY (2009)
FRESH FROM THE PIPELINE Dronedarone
Richard L. Page et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Chemokine Receptor Blockade With a Synthetic Nonpeptide Compound Attenuates Cardiac Allograft Vasculopathy
Sam Bastani et al.
TRANSPLANTATION (2009)
Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of Cxcr3-/- mouse recipients
J. Kwun et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3
Martin E. Hayes et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor
Andrea Meiser et al.
JOURNAL OF IMMUNOLOGY (2008)
Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection
Gabriel T. Schnickel et al.
JOURNAL OF IMMUNOLOGY (2008)
Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors
Dennis Verzijl et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Effects of Blocking the Chemokine Receptors, CCR5 and CXCR3, With TAK-779 in a Rat Small Intestinal Transplantation Model
Hengjie Xu et al.
TRANSPLANTATION (2008)
Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3
Michael Johnson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Inhibition of Gαi2 activation by Gαi3 in CXCR3-mediated signaling
Brian D. Thompson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
A novel CCR5/CXCR3 antagonist protects intestinal ischemia/reperfusion injury
T. Akahori et al.
TRANSPLANTATION PROCEEDINGS (2006)
Detection of redox-based modification in two-dimensional electrophoresis proteomic separations
David Sheehan
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Interferon (IFN)-γ-inducible protein-10:: Association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-α2a and ribavirin for chronic hepatitis C virus infection
Ana I. Romero et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Anti-CXCR3 staining is useful for detecting human cutaneous and mucosal mast cells
Noriko Fukiwake et al.
JOURNAL OF DERMATOLOGY (2006)
Binding of human serum amyloid P component to L-selectin
D Stibenz et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells
BY Ma et al.
BLOOD (2005)
A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection
S Akashi et al.
TRANSPLANTATION (2005)
The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis
H Tokuyama et al.
INTERNATIONAL IMMUNOLOGY (2005)
Structure-activity relationships of different β-lactam antibiotics against a soluble form of Enterococcus faecium PBP5, a type II bacterial transpeptidase
AM Hujer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Among CXCR3 chemokines, IFN-γ-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-γ (CXCL9) imprints a pattern for the subsequent development of autoimmune disease
U Christen et al.
JOURNAL OF IMMUNOLOGY (2003)
Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease
J Kao et al.
CIRCULATION (2003)
Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties
P Proost et al.
BLOOD (2001)
Potential role of the chemokine receptors CXCR3, CCR4, and the integrin αEβ7 in the pathogenesis of psoriasis vulgaris
JB Rottman et al.
LABORATORY INVESTIGATION (2001)
Requirement of the chemokine receptor CXCR3 for acute allograft rejection
WW Hancock et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
